n
 
About Us       Blog       Clients       Disclaimer       Market Basics       Partners       Quotes & News       Video       Contact Us
The QualityStocks Daily Newsletter for Friday, March 10th, 2017

The QualityStocks
Daily Stock List

graphic
graphic

Reign Sapphire Corp. (RGNP)

We are reporting on Reign Sapphire Corp. (RGNP) today, here at the QualityStocks Daily Newsletter.

Reign Sapphire Corp. is a jewelry company that sells branded, custom, as well as fine jewelry direct to consumers. The Company has three niche brands. These brands are Reign Sapphire, the Coordinates Collection, and Le Bloc. Reign Sapphire has its corporate headquarters in Beverly Hills, California. The Company’s shares trade on the OTC Markets Group’s OTCQB.

Reign Sapphire formed as a "source to retail" model for fine sapphires - rough sapphires to finished jewelry, a color gemstone brand, and a jewelry brand featuring Australian sapphires. The history of sapphire gems in Australia goes back more than 150 years.

The Reign Sapphire brand is ethically produced, direct mine-to-consumer sapphire jewelry targeting millennials. The Coordinates Collection is custom jewelry, inscribed with location coordinates commemorating life's special moments. It is the customizable and handmade jewelry line based in Los Angeles, California. The Le Bloc brand is classic customized jewelry.

Reign Sapphires are guaranteed natural gems of certified origin. They undergo manufacture under guaranteed ethical and sustainable processes. The Company’s brands center on elevating products into personal keepsakes, which are built on quality with an innovative, customized point of view.

Reign Sapphires are guaranteed natural and guaranteed Australian. Reign Sapphires are mined in an environmentally friendly manner, ethically processed with jewelry manufactured in the United States.

Last month, Reign Sapphire announced the consumer product launch of the Luna Collection by Coordinates Collection, designed and hand-crafted in Los Angeles, California. The Luna Collection launch is the first launch of 2017 for the Coordinates Collection. This collection comprises a matching bracelet and necklace, which can be engraved with the longitude and latitude of any location, personal message, and date.

In addition, in February, Reign Sapphire announced the launch of Reign Bridal. Reign Bridal launched with its signature Sapphire Eternity Band, a ring designed with inverted blue sapphires.

Reign Sapphire Corp. (RGNP), closed Friday's trading session at $0.122, up 1.67%, on 2,400 volume with 2 trades. The average volume for the last 60 days is 3,926 and the stock's 52-week low/high is $0.0001/$1.00.

Digerati Technologies, Inc. (DTGI)

MicrocapVoice, OTCPicks, AllPennyStocks, and SmallCapVoice reported earlier on Digerati Technologies, Inc. (DTGI), and we report on the Company today, here at the QualityStocks Daily Newsletter.

Digerati Technologies, Inc. is a diversified holding company listed on the OTCQB. It has subsidiary operations in the cloud communications industry. The Company, through its wholly-owned subsidiary, Shift8 Technologies, Inc., provides Internet-based telephony products and services via its cloud telephony application platform and session-based communication network. Digerati Technologies has its headquarters in San Antonio, Texas.

Digerati Technologies serves traditional carriers, telephony resellers, and other VoIP (Voice over Internet Protocol) carriers in the United States and around the world. The Company’s Shift8 Networks subsidiary is an enterprise hosted PBX and cloud-based Unified Communications service provider. Shift8 Networks provides voice, video, and mobile communications to thousands of businesses through its Channel Alliance program.

Shift8 integrates hosted VoIP with cloud-based messaging and desktop applications. Recently, Digerati Technologies announced that Shift8 Networks entered into a new partnership with Tenfold, the foremost phone intelligence platform for the entire customer lifecycle. Through this new partnership, Shift8’s clients can now connect their cloud communication system with over 25 Customer Relationship Management (CRM) systems and Help Desk applications quickly.

Digerati Technologies provides voice over Internet protocol (VoIP) communication services to telecommunications enterprises. It provides Internet-based services. These include fully hosted IP/PBX services, IP trunking, call center applications, prepaid services, and interactive voice response auto attendant. Additionally, services include call recording, simultaneous calling, voicemail to email conversion, and multiple customized IP/PBX features in a hosted or cloud environment for specialized applications.

Regarding oil & gas services, Digerati Technologies continues to investigate opportunities in this industry. It does so through its wholly-owned subsidiary, Flagship Energy Company. Flagship Energy's vision is to build a traditional energy company, partnered with the financial community, to identify and acquire high-quality assets for growth.

Last month, Digerati Technologies announced the re-direction of its corporate resources for building long-term sales and revenue growth, profitability, and corresponding shareholder value. Its plan includes a focus on its cloud communication subsidiary’s business - Shift8 Networks. The Company’s plan also includes a focus on the large U.S. market of small-to-medium sized business (SMB).

Furthermore, Digerati’s plan includes targeting local and/or regional VoIP/cloud telephony providers for acquisition that have excelled in their marketplace; and an ongoing focus on its organic sales strategy of enabling Value Added Resellers (VAR) to offer cloud and session-based communication services to the enterprise market, mainly the SMB.

Additionally, Digerati’s plan includes continued development of its product portfolio taking advantage of its Unified Communications platform to deliver voice, video, messaging, fax, mobile-enabled services, and web conferencing across numerous devices in an integrated user environment; and continued enhancement of its infrastructure and back office systems to streamline operations and automate processes for efficiency, all of which supports its acquisition model, and the scalability of its VAR model.

Digerati Technologies, Inc. (DTGI), closed Friday's trading session at $0.8078, up 58.39%, on 117,200 volume with 109 trades. The average volume for the last 60 days is 2,497 and the stock's 52-week low/high is $0.05/$0.90.

TransAKT Ltd. (TAKD)

We are highlighting TransAKT Ltd. (TAKD) today, here at the QualityStocks Daily Newsletter.

TransAKT Ltd. is a manufacturer of highly inventive agricultural equipment used to grow a wide assortment of vegetables and fruit using simulated sunlight from LED lamps in an indoor proprietary hydroponic system. Moreover, the Company is a global distributor of LED lighting products focused on serving the fastest developing market of commercial, hospitality, and outdoor lighting.

TransAKT’s wholly-owned subsidiary is Vegfab Agriculture Technology Co., Ltd. Vegfab was formed in 2010 by a team of ecologically minded semiconductor specialists knowledgeable about LED materials. TransAKT has its headquarters in Hong Kong.  

In addition, TransAKT is looking for opportunities to develop a BIO-technology business in China. It says that the cordyceps business is one project with the greatest potential. It has engaged a team of about 10 experts in BIO technology engineering to develop an extended product mix that will debut in China in the next few years.

TransAKT’s dedication is to helping business owners protect the environment through superior energy efficiency - replacing present non-energy-efficient light sources with energy-efficient light sources. TransAKT is also concentrating on eliminating the use of chemical fertilizers and pesticides using the latest hydroponic agricultural technology and pure nutrients. The nutrient solutions used in production with its hydroponic systems leave no heavy metal and chemical residues. TransAKT’s product line includes commercial production and home growing systems.

Vegfab’s product line includes systems for commercial production and a home growing system that enables families to grow safe and clean fruit and vegetables in their homes. Vegfab products are the subject of many patents. These include ones for vertically wall-mounted LED lights, and ventilation systems for grow boxes.

Vegfab provides complete growing systems consist of proprietary simulated sunlight LED boards; growing racks in different configurations for commercial and residential applications; environment control and plant nutrition control components; portable work tables and ladders; fruit and vegetable seeds and nutrition products; and vegetables.

Vegfab’s vegetable production factory in Yangmei City, Taiwan is the only mass production facility for vegetables in Taiwan. This facility employs ground-breaking technology to produce exceptional yields from a very small space. Production is very efficient via the use of simulated sunlight from LED lamps, up to 85 percent automated.

Regarding the Vegfab Vegetable Factory, with full control of the growing environment there is no need to apply harmful pesticides to the crops. Vegetables grow from seeds to harvest - ready approximately 35 percent faster than vegetables grown in soil.

Mr. Ho Kang-Wing is the Chairman, Chief Executive Officer, President and Director of TransAKT. Mr. Ho has a vision to build TransAKT into an international leader in the advanced agricultural technology industry. He has committed to help TransAKT to develop and promote the hydroponic planting system in China and other Asian countries.

TransAKT Ltd. (TAKD), closed Friday's trading session at $0.04, down 76.19%, on 5,200 volume with 2 trades. The average volume for the last 60 days is 6,956 and the stock's 52-week low/high is $0.01/$0.25.

Diamante Minerals, Inc. (DIMN)

We are highlighting Diamante Minerals, Inc. (DIMN) today, here at the QualityStocks Daily Newsletter.

Diamante Minerals, Inc. is an exploration stage natural resources company focusing on the diamond sector. The Company works to identify, explore, and develop first-rate diamond bearing properties around the world. It previously went by the name Oconn Industries Corp. It changed its name to Diamante Minerals, Inc. in April 2014. Diamante Minerals is headquartered in Kelowna, British Columbia.

Diamante is concentrating on acquiring its initial 20 percent interest in the Batovi Diamond Project and also in developing the Project. The Batovi Diamond Project was optioned by Diamante Minerals and it is 220 kilometers north of the town of Paranatinga in Mato Grosso, Brazil. The landlocked province of Mato Grosso is in central Brazil.

Mato Grosso has been the focus of much of Diamante’s exploration work in the country. Surveys in this area have shown the presence of indicator minerals. These include garnets and chrome spinels. This represents a clear sign that kimberlite is a possibility. The Batovi Diamond Project represents a premier opportunity for the discovery of diamond bearing kimberlite intrusives. Also, the Batovi Diamond Project has potential for the development of alluvial diamond production from diamondiferous gravels associated with the Rio Batovi drainage basin and its tributaries.

Moreover, Diamante Minerals has a gold stream agreement for the Molejon Gold Mine in the Donoso District, Colon Province of Panama. Diamante negotiated a royalty of 12.5 percent on 1,000 ounces of gold produced monthly for 12 months.  In the event monthly production is more than 1,000 ounces, Diamante is to receive an additional 5 percent royalty.

Production at the Molejon Mine commenced in 2009, with an initial throughput of 2,200 tons per day (tpd).  In September of 2011, the mine had proven and probable mineral reserves of 643,266 ounces of gold and certain additional mineralized material. In 2012, the plant underwent expansion to 3,500 tpd, resulting in an annual gold equivalent production of 69,000 ounces in 2012 and again in 2013 before closing late in the year.

Recently, Diamante Minerals announced that it amended its Mineracao Batovi Agreement in Brazil. In addition, the Company announced that it acquired a 2.4 percent Interest in the Batovi Project. With the amended agreement, the joint venture (JV) to develop the Mineracao Batovi project will be effected via holdings in Mineracao Batovi Ltda. the Brazilian company presently holding the Mato Grosso claims as opposed to through a newly formed JV company as originally contemplated.

Diamante Minerals, Inc. (DIMN), closed Friday's trading session at $0.16232, up 15.94%, on 6,470 volume with 4 trades. The average volume for the last 60 days is 60,673 and the stock's 52-week low/high is $0.10/$0.55.

Endonovo Therapeutics, Inc. (ENDV)

Innovative Marketing, SeeThruEquityResearch, HEROSTOCKS, Stock Brain, SmallCapVoice, Buzz Stocks, Damn Good Penny Picks, Penny Pick Finders, PennyStockProphet, Planet Penny Stocks, SecretStockPromo, StockOnion, BestDamnPennyStocks, DSR News, Penny Picks, Penny Stock Newsletter, PHUB News, PREPUMP STOCKS, Stock Commander, TheNextBigTrade, and OTC Markets Group reported earlier on Endonovo Therapeutics, Inc. (ENDV), and we report on the Company today, here at the QualityStocks Daily Newsletter.

Endonovo Therapeutics, Inc. is a biotechnology company based in Woodland Hills, California. It is a leading developer of bioelectronic-applications in cell therapies and non-invasive electroceuticals. The Company’s initial focus is on the treatment of acute and chronic inflammatory conditions of the liver using its proprietary Immunotronics™ platform and the treatment of Graft-Versus-Host Disease using its ex vivo expanded and enhanced stem cells. Endonovo Therapeutics is centering its efforts on inflammatory conditions in vital organs.

The Company’s Immunotronics™ platform is a non-invasive, non-implantable bioelectronic device for treating/preventing vital organ failure through the reduction of inflammation, cell death and the promotion of regeneration. Endonovo’s Cytotronics™ platform provides for a method of expanding and manipulating cells using simulated microgravity and Time-Varying Electromagnetic Fields (TVEMF) for tissue engineering and cell therapies.

The purpose of Endonovo’s Cytotronics™ platform is to create optimized cell-based therapies with greater therapeutic potential than the un-modulated cells presently being used in regenerative medicine. The basis for its Time-Varying Electromagnetic Field (TVEMF) technology was created at NASA in combination with the development of cell therapies to treat injuries and diseases that astronauts might encounter during long term manned missions in space.

Endonovo is in the pre-clinical phase of evaluating its proprietary Immunotronic technology in the treatment of chronic and acute inflammatory conditions in the liver, including fulminant liver failure. It is developing a next-generation, off-the-shelf treatment for Graft-Versus-Host Disease (GVHD) using Cytotronics™ expanded and ex vivo enhanced stem cells from the human umbilical cord.

Endonovo Therapeutics is expanding its liver disease research program and its Cytotronics™ platform to create a high-fidelity drug development and toxicology testing platform. The Company’s Cytotronics™ platform utilizes bioelectronics to control and enhance cell functions. This allows 3D intelligent cell cultures to be implemented in growing and enhancing stem cells and tissues for the development of cell therapies, disease modeling, ADME (absorption, distribution, metabolism, and excretion) and toxicology testing.

Endonovo announced this past December that it is starting a pre-clinical study at a contract research organization to measure the therapeutic potential of its Immunotronics™ platform in the prevention of heart failure following myocardial infarction (MI). The pre-clinical study will evaluate the effect of Endonovo's non-invasive electroceutical technology on cardiac function, post-MI remodeling, and infarct size, and also angiogenesis (the development of new blood vessels).

Endonovo Therapeutics, Inc. (ENDV), closed Friday's trading session at $0.031, up 96.20%, on 13,257,599 volume with 459 trades. The average volume for the last 60 days is 1,108,021 and the stock's 52-week low/high is $0.0092/$0.875.

graphic

The QualityStocks
Company Corner

graphic
graphic

India Globalization Capital, Inc. (IGC)

The QualityStocks Daily Newsletter would like to spotlight India Globalization Capital, Inc. (NYSE: IGC). Today, India Globalization Capital, Inc. closed trading at $0.2947, up 1.62%, on 95,528 volume with 246 trades. The stock’s average daily volume over the past 60 days is 168,069, and its 52-week low/high is $0.19/$0.83.

India Globalization Capital, Inc. (IGC) is a first mover in developing a portfolio of products using cannabis-based "combination therapies" for the treatment of pain and other conditions.

The national cost of health care due to pain ranges from $560 billion to $635 billion. In addition, the health care cost attributed to the abuse of prescription opioids, closely related to pain, is approximately $25 billion. IGC's patent filing (IGC-501) is a cannabis-based formulation addressing neuropathic and arthritic pain in joints and muscles using a variety of delivery techniques. The Company anticipates commencing clinical trials, and hopes that through its focus on combination therapy it can formulate and commercialize cannabinoid compounds as an alternative to long-term addictive opioid treatments.

The Company has also filed combination therapy formulations for the treatment of epilepsy and cachexia. About 50 million people worldwide are affected by epilepsy and about 1.3 million in the U.S. experience cachexia associated with cancer, MS, Parkinson's, HIV/AIDS and other progressive illnesses. Cancer-induced anorexia/cachexia is responsible for 20% of all cancer deaths. IGC-502 indicated for seizures and IGC-504 indicated for cachexia are unique combination therapies that, if proven out by clinical trials, are expected to treat medical refractory epilepsy and eating disorders respectively, with lower side effects than conventional mono therapies.

IGC's strategy is exciting and unique in that it is aiming to become a leader in the phytocannabinoid-based combination therapy specialty pharmaceutical sector. This first mover advantage can potentially be formidable as it begins clinical trials and further builds its patent portfolio. "The development of combination therapies utilizing cannabis represents a large, unique opportunity in this emerging specialty-pharmaceutical sector. Securing FDA approval for combination therapy is believed to be significantly faster and less expensive than new drug applications. As a result, we believe that we can bring our cannabis-based pharmaceutical products to market in both an expeditious and cost-effective manner," stated Ram Mukunda, CEO.

IGC has recently exited its legacy businesses and currently holds international investments in land and in a hotel project. An impressive and experienced team, led by Mr. Ram Mukunda, CEO, directs IGC.

Mr. Mukunda holds degrees in Electrical Engineering and Mathematics from the University of Maryland (UMD). He founded and served as Chairman and CEO of Startec Global Communications, an international telecommunications carrier focused on providing voice over Internet protocol (VOIP) services to emerging economies. Startec, the first pure play international long distance carrier, went public on NASDAQ. He has won a number of awards, including the 2013 University of Maryland International Alumnus of the year award. Mr. Mukunda serves as an Emeritus member on the Board of Visitors at the University of Maryland, School of Engineering, and has served as Council Member at Harvard's Kennedy School of Government, Belfer Center of Science and International Affairs. Mr. Mukunda and Dr. Krishna are the originators of all the IGC patent filings.

Dr. Ranga Krishna, Senior Advisor, is a Board Certified Neurologist with a sub specialty in Epilepsy surgery. He is the Director of Neurology at the New York Community Hospital affiliated with New York Presbyterian Weil Cornell Medical College and the Director of Stroke Service at the New York Community Hospital affiliated with New York Presbyterian Weil Cornell Medical College. He is the Medical Director and Chairman of Total Neuro Care, P.C. He is CEO of International Pharma Trials, Inc., which assists U.S. pharmaceutical companies perform Phase II clinical trials. Dr. Krishna is a member of several organizations, including the American Academy of Neurology and the Medical Society of the State of New York. He is also a member of the Medical Arbitration panel for the New York State Workers' Compensation Board and a Founding Member of the New York State Pain Society. Dr. Krishna was trained at New York's Mount Sinai Medical Center (1991-1994) and New York University (1994-1996). Dr. Krishna and Mr. Mukunda are the originators of all the IGC patent filings. Disclaimer

India Globalization Capital, Inc. Company Blog

India Globalization Capital, Inc. News:

IGC Announces Third Quarter Financial Results

India Globalization Capital Announces the Extension of Warrants’ Expiry Date and Inducement Grant to its CFO

IGC Update on Iron Ore Subsidiary

Players Network, Inc. (PNTV)

The QualityStocks Daily Newsletter would like to spotlight Players Network, Inc. (PNTV). Today, Players Network, Inc. closed trading at $0.029, up 7.41%, on 1,144,636 volume with 43 trades. The stock’s average daily volume over the past 60 days is 2,111,540, and its 52-week low/high is $0.0022/$0.048.

Players Network, Inc. (PNTV) is a diversified holding company operating in marijuana and media. PNTV owns 86% of Green Leaf Farms Holdings, LLC (Green Leaf Farms) which has Nevada state-issued cultivation and production license(s). The cultivation license enables Green Leaf Farms to grow marijuana and the production license enables them to create extracts which are used for cartridges, oils and edibles. WeedTV.com is a wholly owned subsidiary which is developing the ultimate resource for the marijuana lifestyle. PNTV has been a fully reporting, publicly traded company since 1998.

Green Leaf Farms Holdings, LLC (Green Leaf)

Green Leaf produces medical and recreational cannabis products. Revenues are generated by selling their cannabis products to licensed dispensaries throughout Nevada.

Their mission is to produce the highest quality and safest pharmaceutical-grade cannabis to all levels of consumers. They utilize the most efficient cultivation methods in order to lower expenses for consumers and to maximize returns for investors.

They are a privately held company with a unique business model as they are one of only a few companies who have been granted 2 (two) Medical Marijuana Establishment (MME) licenses in Nevada; Cultivation and Production.

Their Cultivation License enables them to grow cannabis which will produce flower. Their Production License enables them to process flower (cannabis) and cannabis byproducts into extremely pure concentrates, extracts, and oils which are used in medicine, cartridges and edibles. Green Leaf has both acquired and developed proprietary cannabis strains and will continue to be committed to cannabis research and development.

Green Leaf is located in North Las Vegas, Nevada on 2.3 acres in a state-of-the-art 26,000 sq. ft. facility. They have a seasoned team of professional growers and operators to manage the facility with proven best practices to ensure they have the highest quality products available.

WeedTV.com

WeedTV.Com is a niche social network and lifestyle channel destination for the marijuana industry. They are developing the "go-to" source for information, entertainment, products and services for people who relate to the marijuana lifestyle and an active social community. WeedTV.com features daily stories sourced by WeedTV.com correspondents and contributors from around the world.

Programming includes, political news, business news on the industry, financial analysis from industry experts, growing tips, cooking tips, the "Weed101" section, medical applications/issues, lifestyle features, and entertainment specials.

WeedTV.com's first original series is titled "High Stakes." High Stakes was developed by Michael Berk, the company's Chief Creative Officer and creator of one of the most popular cable series of all time, Baywatch. High Stakes is docu-series that follows the team at Green Leaf Farms as they build their facility and launch their marijuana business.

By leveraging media, WeedTV.com builds long-term brand equity and connects consumers to businesses. This is accomplished through fresh and relevant content such as professionally produced branded television segments, user-generated videos, blogs, editorials, tweets (twitter), photos, special offers, events and custom-designed contests to engage both consumers and businesses with their brands and services.

Marijuana and Media Strategy

While developing WeedTV.com, the PNTV team realized they could implement a vertical strategy to utilize their media platform (WeedTV.com) to drive business and awareness to their cannabis products (Green Leaf Farms). Through the audience and reach of WeedTV.com, they will build brand value and cross market their own marijuana products, as well as generate revenues by marketing other companies' products and services. Disclaimer

Players Network, Inc. Company Blog

Players Network, Inc. News:

Players Network (OTCQB: PNTV) Featured on MoneyTV with Donald Baillargeon, 2/17

Player's Network, Inc. Commences Trade on OTCQB

Player's Network Announces $350,000 Investment from CEO Mark Bradley

InMed Pharmaceuticals, Inc. (IMLFF)

The QualityStocks Daily Newsletter would like to spotlight InMed Pharmaceuticals, Inc. (IMLFF). Today, InMed Pharmaceuticals, Inc. closed trading at $0.2679, up 3.00%, on 364,932 volume with 165 trades. The stock’s average daily volume over the past 60 days is 817,566, and its 52-week low/high is $0.05/$0.4261.

InMed Pharmaceuticals, Inc. (IMLFF) is a preclinical-stage biopharmaceutical company specializing in the development of novel therapeutics leveraging the pharmacological benefits of cannabinoids. Utilizing its proprietary bioinformatics assessment tool, InMed aims to identify bioactive compounds found within the cannabis plant that have the potential to offer optimized therapeutic benefit while demonstrating limited adverse effects. This assessment tool, in combination with the company’s cannabinoid biosynthesis technology and drug development pipeline, serves as InMed’s fundamental value driver.

Bioinformatics is a proprietary, computer-based program designed to assist in the identification of novel cannabinoids using comprehensive algorithms to integrate data from numerous bioinformatics databases, as well as a database on the structure of currently approved pharmaceutical products and an extensive database on over 90 individual cannabinoid drugs found in cannabis. This extensive collection of data is derived from both public and propriety-based sources. Leveraging this tool, the company aims to create associations between approved pharmaceuticals and cannabinoids with similar structures in order to identify active cannabinoids that have the potential to treat specific diseases. Per InMed’s website, this type of bioinformatics assessment represents “significant promise for future drug discovery, as it integrates many data sets and builds holistic models to approach a specific disease.”

After discovering these promising active cannabinoids, InMed moves to test and confirm their activity in biological systems through in vitro and in vivo experimentation. It is at this stage of development that the company’s proprietary biosynthesis process of cannabinoid manufacturing will be most promising. InMed is currently developing a robust, high-yield biosynthesis process for manufacturing all 90+ naturally-occurring cannabinoids. By modifying the agriculture-based formula for harvesting cannabinoids, InMed aims to combine the inherent safety and known efficacy of the natural drug structure with the convenience, control and quality of 21st Century laboratory-based manufacturing processes.

The company’s pipeline currently includes two drug candidates in preclinical development, including INM-750 for the treatment of epidermolysis bullosa (EB) and INM-085 for the treatment of glaucoma. Referred to by the Dystrophic Epidermolysis Bullosa Research Association of America as “The Worst Disease You’ve Never Heard Of,” EB is a rare genetic connective tissue disorder that affects roughly one out of every 20,000 births in the United States. The condition currently has no approved treatment or cure. Through the development of INM-750, InMed is attempting to address this significant unmet medical need. The drug candidate replaces missing keratins in the skin with specially selected cannabinoids in an effort to modulate the painful manifestations of EB.

INM-085, InMed’s second development candidate, is formulated to reduce the elevated intra-ocular pressure that is often associated with glaucoma. Additionally, the cannabinoids utilized in INM-085 are expected to provide neuroprotection for the retinal ganglion cells and other optic nerve tissues following topical administration. Although it is still in preclinical development, INM-085 targets a sizable market. According to the Glaucoma Research Foundation, glaucoma is a leading cause of blindness with no approved cure. The National Institutes of Health estimates that more than 3 million Americans currently have glaucoma, and more than 120,000 have been blinded by the disease.

InMed is focused on progressing toward validation of its drug candidate selection, using data to secure its patents and developing key disruptive technologies. In 2016, the company was successful in completing financings of $1.9 million. In January 2017, InMed completed a non-brokered private placement of common shares generating aggregate gross proceeds of C$1.5 million, strongly positioning the company to attract the new investment required to fund its aggressive growth strategies in 2017.

The company’s management team has well over a century of combined experience in the biopharmaceutical space. Company CEO Eric Adams has more than 25 years of experience in company and capital formation, global market development, mergers and acquisitions, licensing and corporate governance. During his time as CEO of enGene Inc., he led the gene therapy startup to a position at the head of the industry.

Joining Adams on the InMed management team are Chief Scientific Officer Dr. Sazzan Hossain; Senior Vice President, Clinical and Regulatory Affairs Alexandra D.J. Mancini; SVP, Corporate Strategy & Investor Relations Chris Bogart; and Chief Financial Officer Jeff Charpentier, as well as Chief Medical Officer Dr. Ado Muhammed, MD, DPM, MFPM.

Muhammed, in particular, has an extensive history in the pharmaceutical industry, having previously served as an executive of GW Pharmaceuticals, a global leader in the development of cannabinoid-based medicines. During his time as Associate Medical Director of that company, Muhammed played an instrumental role in the development and FDA approval of one of the first cannabis drugs. This GW Pharmaceuticals development program coincided with a sharp rise in share price from less than $9 in 2013 to more than $129 today, with the company’s current market value totaling more than $2.9 billion. Disclaimer

InMed Pharmaceuticals, Inc. Company Blog

InMed Pharmaceuticals, Inc. News:

InMed Pharmaceuticals Files PCT Patent for Epidermolysis Bullosa Simplex

InMeds Bioinformatics Platform Powers Cannabinoid Drug Development -- CFN Media

InMed Receives over $1,350,000 From Warrant Exercise

ORHub, Inc. (ORHB)

The QualityStocks Daily Newsletter would like to spotlight ORHub, Inc. (ORHB). Today, ORHub, Inc. closed trading at $0.70, up 2.94%, on 289,351 volume with 144 trades. The stock’s average daily volume over the past 60 days is 47,044 and its 52-week low/high is $0.05/$2.09.

ORHub, Inc. (ORHB) is a cloud-based software platform designed to transform the business of surgery into a value-based model. The platform empowers care providers at every stage of the surgical process to collaborate, organize, deliver, measure, and reimburse in one intuitive, easy-to-use program. This significantly decreases cost and improves outcomes by eliminating inefficiencies, duplications of effort, and errors and omissions that result from siloed processes in outdated software and poor handoffs from one part of the care process to another.

The need for ORHub is clear. Health care costs are out of control at more than 17% of US GDP, which equates to over $3 trillion per year. With costs rising every year due to an aging population and increasingly expensive treatments, providers are under severe pressure to become more efficient and reduce costs. This is happening because payors are aggressively reducing reimbursements and finally moving away from fee-for-service and toward a performance-based reimbursement system referred to as value-based health care.

Accurately measuring the cost of treating a condition and relating that cost to the patient's outcome is at the heart of value-based health care. Institutions that have adopted this model have reaped savings of 20-40% on their overall cost of care. Unfortunately, today's siloed IT systems are fundamentally at odds with this process. Legacy health care solutions come from a fee-for-service world and have reinforced the problem and produced a system with erratic quality and unsustainable costs. Most health care applications today are incremental improvements on these existing systems or are simple digital implementations of antiquated pen-and-paper processes.

Providers wanting to practice value-based health care need value-based software. ORHub creates a value-based solution that will revolutionize surgical care delivery by tracking the cost of treating a condition from diagnosis to discharge, and tracking outcomes that resulted from that treatment.

In an industry where major IT rollouts traditionally cost millions of dollars and take an average of eighteen months, pilot installations of ORHub have been completed in less than a month. By avoiding integration with legacy systems completely through a radically comprehensive and collaborative approach, providers see results right away. This approach produces real-time metrics in a uniform manner at any institution, which makes it ideal for large providers looking to make improvements across the board at multiple facilities.

ORHub started as a pilot program developed in cooperation with a major Southern California hospital. It has since expanded operations into a second facility at the number two non-profit hospital system in the US. Three additional pilot programs are scheduled prior to a national launch. The company has raised more than $1.6 million as of January 2017.

The company is also a showcase member of the startup program at Microsoft, which has been a key partner by providing financial assistance, strategy, introductions to influencers and mentors, and access to its sales organization who see ORHub as an exciting partner to expand the utilization of Microsoft Surface devices and Azure Cloud. Microsoft is funding a major case study in partnership with Intel about the impact of ORHub on participating institutions to be concluded sometime in Q2 2017.

ORHub's leadership team is helmed by Colt Melby, who was appointed CEO in 2016 and has been crucial to developing and executing the company's business strategy. Mr. Melby's extensive business experience includes the NASDAQ uplisting of Smith and Wesson (now American Outdoor Brands), CUI Global Inc., and Quest Resource Holdings Corp. His wealth of information and relationships have been vital in helping the company go from concept to production in institutional medicine in less than a year.

Delivering surgical care to a single patient is a complex process that may take half a dozen companies and more than a dozen departments cooperating inside and outside the care facility. ORHub simplifies and streamlines this process by enabling vendors, providers, and surgeons to collaborate on providing care. Disclaimer

ORHub, Inc. Blog

ORHub, Inc. News:

NetworkNewsWire Releases Exclusive Audio Interview with ORHub, Inc. (ORHB)

ORhub, Inc. (ORHB) Engages NetworkNewsWire for Corporate Communications Solutions

ORHub, Inc. (ORHB) Expands Operations at Nation's Second Largest Non-Profit Hospital System

ChineseInvestors.com (CIIX)

The QualityStocks Daily Newsletter would like to spotlight ChineseInvestors.com (CIIX). Today, ChineseInvestors.com closed trading at $1.6397, up 1.22%, on 94,528 volume with 168 trades. The stock’s average daily volume over the past 60 days is 198,952 and its 52-week low/high is $0.12/$2.75.

Founded in 1999, ChineseInvestors.com (CIIX) has become a leading financial information website for Chinese-speaking investors in the United States and China. Recognizing unprecedented opportunities in the U.S. cannabis industry, CIIX is also laying the groundwork to capitalize on growing demand for cannabidiol (CBD)-based nutrition and health products.

Through its primary website, www.ChineseInvestors.com, CIIX offers a variety of investor education products and services, including real-time market commentary, analysis and educational related services in Chinese language character sets; consultative services to smaller private companies considering becoming a public company; and advertising and public relations related support services.

At the center of this initiative is the ChineseInvestors Method, a unique integration of a disciplined investing process, web-based tools, personalized instructions and support. Using this strategy, CIIX provides reliable market information to help investors make informed investment decisions and meet their individualized financial goals.

CIIX is also leveraging its financial expertise to enter into the burgeoning CBD industry, which within a few years has grown from a relatively invisible sector to a billowing market expected to reach $2.1 billion in consumer sales by 2020.

The increasing demand for CBD-based products is a catalyst for innovative business endeavors. To this accord, CIIX has established a three-year development plan to capitalize on the convergence of CBD and the nutrition and health products market in mainland China, where the benefits of CBD oil have not been widely recognized.

Under a wholesale agreement with a reputable CBD health brand, CIIX is launching the world's first online CBD health products store published in the Chinese language. The site, www.ChineseCBDoil.com, caters to a growing number of Chinese people awakening to the numerous health benefits of CBD oil for treatment of a variety of conditions such as anxiety, stress, poor sleep, Alzheimer's disease, and more. CIIX expects to launch this website at the end of January 2017, and plans to sell CBD-infused products via online and in-store.

In conjunction, CIIX's cannabis-focused "Yelp"-style mobile app is in development as a platform for Chinese people to review and discuss various cannabis products. The app will be the first marijuana social media mobile app designed for Chinese-speaking customers worldwide. Disclaimer

ChineseInvestors.com Blog

ChineseInvestors.com News:

SeeThruEquity Issues Update on ChineseInvestors.com Inc. (OTCQB: CIIX), Increasing Price Target to $3.75

ChineseInvestors.com, Inc. to Present at the National Investment Banking Association Conference in New York City on February 28, 2017

ChineseInvestors.com Presents at Yibao Biologics' Annual Conference, Optimistic About Direct Selling Opportunity in China

graphic

Rate Us
Tell us how we're doing!
Click here to begin your review.

Today's Top 3
Investment Newsletters

graphic

1.

QualityStocks
(ENDV) +96.20%

2.

Wall Street Mover
(HELIQ) +76.27%

3.

StockMarketWatch
(CERC) +64.38%

graphic
By The Numbers Charts
QualitystockTwits

The QualityStocks Public Company Sponsor News

Featured Sponsor

Daily Sponsors
















 

The QualityStocks By The Numbers Report

Click the chart below to see the full report

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market
each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge"
based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.

 

About Us     Archives     Blog     Clients     Disclaimer     Market Basics    Partners      Quotes & News     Video     Contact Us

twitter icon facebook icon

QualityStocks Logo

Copyright © 2006 - 2012. QualityStocks 3370 N. Hayden Rd., Suite 123-591, Scottsdale, AZ 85251